Sanjeeve Balasubramaniam

Employment

• U.S. Food and Drug Administration Medical Officer

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment
  Breast Cancer Research and Treatment 2016 DOI: 10.1007/s10549-016-3972-z
  +Save
• Adrenocortical cancer: A molecularly complex disease where surgery matters
  Clinical Cancer Research 2016 DOI: 10.1158/1078-0432.CCR-16-1570
  +Save
• Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer
  Journal of Clinical Pharmacology 2016 DOI: 10.1002/jcph.625
  +Save
• UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation
  Journal of Clinical Pharmacology 2016 DOI: 10.1002/jcph.627
  +Save
• A phase I study of DMS612, a novel bifunctional alkylating agent
  Clinical Cancer Research 2015 DOI: 10.1158/1078-0432.CCR-14-1333
  +Save
• Advancing clinical trials to streamline drug development
  Clinical Cancer Research 2015 DOI: 10.1158/1078-0432.CCR-15-0039
  +Save
• Expansion cohorts in first-in-human solid tumor oncology trials
  Clinical Cancer Research 2015 DOI: 10.1158/1078-0432.CCR-14-3244
  +Save
• Phase ii clinical trial of Ixabepilone in metastatic cervical carcinoma
  Oncologist 2015 DOI: 10.1634/theoncologist.2015-0104
  +Save
• The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer
  Journal of Clinical Endocrinology and Metabolism 2014 DOI: 10.1210/jc.2013-2298
  +Save
• Targeting the epigenome in lung cancer: Expanding approaches to epigenetic therapy
  Frontiers in Oncology 2013 DOI: 10.3389/fonc.2013.00261
  +Save